| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...990929G |
| P356 | DOI | 10.1371/JOURNAL.PONE.0090929 |
| P932 | PMC publication ID | 3946382 |
| P698 | PubMed publication ID | 24603710 |
| P5875 | ResearchGate publication ID | 260610900 |
| P50 | author | Asmaa Ibrahim Gomaa | Q46617277 |
| Imam Waked | Q46617293 | ||
| P2093 | author name string | Mohamed Saad Hashim | |
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma | Q80816501 | ||
| Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan | Q81021043 | ||
| Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery | Q81688876 | ||
| Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy | Q83014134 | ||
| A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients | Q83277519 | ||
| Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. | Q53557508 | ||
| Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients | Q57205313 | ||
| Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score | Q57763811 | ||
| Treatment and prognostic factors in patients with hepatocellular carcinoma | Q59660608 | ||
| A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients | Q60685449 | ||
| How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system | Q73370171 | ||
| Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis | Q78651615 | ||
| The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? | Q79363825 | ||
| Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan | Q79784508 | ||
| [Prognostic factors for survival in patients with hepatocellular carcinoma after radiofrequency ablation] | Q80427667 | ||
| [Postoperative detection of AFP mRNA in the peripheral blood of hepatic cellular carcinoma patients and its correlation with recurrence] | Q80654856 | ||
| Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials | Q80780780 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Hepatocellular carcinoma | Q29615841 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 | ||
| Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma | Q34098980 | ||
| Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort | Q34446810 | ||
| A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire | Q34504366 | ||
| Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. | Q34522010 | ||
| Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort | Q34556277 | ||
| Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. | Q34584365 | ||
| The prognostic molecular markers in hepatocellular carcinoma | Q34668320 | ||
| Hepatocellular carcinoma in Egypt: a single center study over a decade. | Q35059721 | ||
| Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). | Q35097916 | ||
| Hepatocellular carcinoma in Central Europe: prognostic features and survival | Q35362361 | ||
| Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto | Q35594697 | ||
| Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients | Q35597216 | ||
| Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. | Q35597241 | ||
| Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma | Q35633563 | ||
| Critical evaluation of the different staging systems for hepatocellular carcinoma | Q35719432 | ||
| Advanced hepatocellular carcinoma: which staging systems best predict prognosis? | Q36836103 | ||
| Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology | Q37034867 | ||
| Clinical staging of hepatocellular carcinoma | Q37527610 | ||
| The challenge of prognosis and staging for hepatocellular carcinoma | Q37813315 | ||
| Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis | Q40408726 | ||
| Is there an ideal prognostic model for hepatocellular carcinoma? | Q43004242 | ||
| Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma | Q43550696 | ||
| Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program | Q43722486 | ||
| Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients | Q43850818 | ||
| Comparison of staging systems to predict survival in hepatocellular carcinoma. | Q44131464 | ||
| Prospective validation of the Barcelona Clinic Liver Cancer staging system | Q44369884 | ||
| Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients | Q44628674 | ||
| Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis | Q45185908 | ||
| High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. | Q45601546 | ||
| Risk factors for early recurrence after surgical resection for hepatocellular carcinoma | Q46348590 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Egypt | Q79 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | e90929 | |
| P577 | publication date | 2014-03-06 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt | |
| P478 | volume | 9 |
| Q58576192 | Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis |
| Q28076314 | Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines |
| Q35594282 | Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging |
| Q49545298 | Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma |
| Q36741673 | Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience |
| Q37279353 | Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies |
| Q46867815 | Evaluation of CD44 and CD133 as markers of liver cancer stem cells in Egyptian patients with HCV-induced chronic liver diseases versus hepatocellular carcinoma |
| Q36153539 | Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System |
| Q49648449 | Immunohistochemical and Biochemical Expression Patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-Associated Hepatocellular Carcinomas |
| Q64068788 | Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? |
| Q26748756 | Liver resection for intermediate hepatocellular carcinoma |
| Q33769497 | Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China |
| Q91147767 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q57472351 | Retracted: The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies |
| Q59357037 | Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients |
| Q35594262 | Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence |
| Q38408876 | Staging systems for hepatocellular carcinoma: Current status and future perspectives |
| Q38282463 | Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma |
| Q52699066 | Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). |
| Q36580973 | TNM Staging of Colorectal Cancer Should be Reconsidered According to Weighting of the T Stage: Verification Based on a 25-Year Follow-Up |
| Q48029235 | The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients |
| Q41736718 | The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma |
| Q35701279 | The promise of metabolic phenotyping in gastroenterology and hepatology |
| Q52655170 | Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma. |
| Q92237158 | Urinary 8-hydroxydeoxyguanosine in relation to XRCC1 rs25487 G/A (Arg399Gln) and OGG1 rs1052133 C/G (Ser326Cys) DNA repair genes polymorphisms in patients with chronic hepatitis C and related hepatocellular carcinoma |
| Q33786041 | Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients |
Search more.